Jiunn-Chang Lin, Tsang-Pai Liu, Vivin Andriani, Muhammad Athoillah, Chih-Yang Wang, Pei-Ming Yang
Hepatocellular carcinoma (HCC) is an aggressive and chemoresistant cancer type. The development of novel therapeutic strategies is still urgently needed. Personalized or precision medicine is a new trend in cancer therapy, which treats cancer patients with specific genetic alterations. In this study, a gene signature was identified from the transcriptome of HCC patients, which was correlated with the patients’ poorer prognoses. This gene signature is functionally related to mitotic cell cycle regulation, and its higher or lower expression is linked to the mutation in tumor protein p53 (TP53) or catenin beta 1 (CTNNB1), respectively. Gene–drug association analysis indicated that the taxanes, such as the clinically approved anticancer drug paclitaxel, are potential drugs targeting this mitotic gene signature. Accordingly, HCC cell lines harboring mutant TP53 or wild-type CTNNB1 genes are more sensitive to paclitaxel treatment. Therefore, our results imply that HCC patients with mutant TP53 or wild-type CTNNB1 genes may benefit from the paclitaxel therapy. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Department of Surgery, MacKay Memorial Hospital, Taipei, 10449, Taiwan; MacKay Junior College of Medicine, Nursing, and Management, New Taipei City, 11260, Taiwan; Department of Medicine, MacKay Medical College, New Taipei City, 25245, Taiwan; Liver Medical Center, MacKay Memorial Hospital, Taipei, 10449, Taiwan; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, 11031, Taiwan; Department of Biological Science, Faculty of Science and Technology, Universitas PGRI Adi Buana, Surabaya, 60234, Indonesia; Department of Statistics, Faculty of Science and Technology, Universitas PGRI Adi Buana, Surabaya, 60234, Indonesia; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan; TMU Research Center of Cancer Translational Medicine, Taipei, 11031, Taiwan; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei, 11696, Taiwan
Research at a Glance
Register to unlock
Topics & SDG Alignment
Register to unlock
Collaboration
Register to unlock
Author Profile (Selected)
Register to unlock
References Overview
Register to unlock
Journal & Source
Register to unlock
Metadata & Integrity
Register to unlock